Complete Revascularization after Pharmacoinvasive Strategy

Patients initially receiving pharmacoinvasive strategy for ST elevation myocardial infarction (STEMI) also presenting multivessel disease consistently benefit from complete revascularization. This benefit is similar to that of primary PCI.  

Revascularización completa luego de estrategia fármaco invasiva

The COMPLETE showed that staged non-culprit lesion percutaneous coronary intervention (PCI) reduced major cardiovascular events in STEMI patients with multivessel coronary artery disease. This benefit was not clear for patients initially receiving antithrombotic medication not being able to access PCI right away. 

Following successful culprit lesion PCI, STEMI 4041 patients with multivessel disease were randomized to either routine non-culprit lesion PCI or culprit lesion only PCI. 

In a COMPLETE prespecified analysis, effect in 303 patients undergoing a pharmacoinvasive strategy was determined against 3738 patients undergoing primary PCI. Two primary end points were defined: on the one hand, cardiovascular death or new myocardial infarction and on the other hand, cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. 

The first primary end point was reduced with complete revascularization both in the patients undergoing a pharmacoinvasive strategy (2.1% vs 4.7%, HR 0.45, 95% CI, 0.21–0.97) and in patients undergoing primary PCI (2.7% vs 3.6%, HR 0.77, 95% CI, 0.62–0.95; interaction P=0.18). 


Read also: SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection.


The second primary end point was also reduced significantly with complete revascularization in patients undergoing an initial pharmacoinvasive strategy and in patients undergoing primary PCI.

Conclusion

Patients with multivessel disease with STEMI benefit from complete revascularization after treating the culprit lesion both with primary PCI and initial pharmacoinvasive strategy. 

Orignal Title: Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial.

Reference: Payam Dehghani et al. Circ Cardiovasc Interv. 2021 Aug;14(8):e010458. doi: 10.1161/CIRCINTERVENTIONS.120.010458.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....